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Background. Sclerosing melanocytic lesions, which are characterized by either focal or diffuse sclerosis in the dermal 
component and atypical proliferation of predominantly nevoid melanocytes, remain poorly defined. Our aim was to 
analyze systematically their morphologic spectrum, especially the distinction between sclerosing melanocytic nevus 
and sclerosing melanoma, which has not been well documented.
Patients and methods. We collected 90 sclerosing melanocytic lesions, occurring in 82 patients (49 male, 33 fe-
male; age range from 21 to 89 years). A four probe fluorescent in situ hybridization (FISH) assay was performed in 41 
lesions to substantiate the diagnosis of sclerosing melanomas.
Results. A prominent full-thickness pagetoid spread of melanocytes was identified in 44 (48%) lesions, and a mela-
noma in situ adjacent to the sclerosis in 55 (61%) lesions. In the intrasclerotic component, maturation was absent in 40 
(44%) and mitotic figures were identified in 18 (20%) lesions. Of the 90 lesions, 26 (29%) were diagnosed morphologi-
cally as nevi and 64 (71%) as melanomas (Breslow thickness from 0.4 to 1.8 mm), including 45 (50%) melanomas with 
an adjacent nevus. A four-probe FISH assay was positive in the sclerotic component in 14 of 25 lesions diagnosed 
morphologically as melanomas and none of 16 nevi. A sentinel lymph node biopsy was performed for 17 lesions and 
was negative in all cases. 
Conclusions. Sclerosing melanocytic lesions form a morphologic spectrum and include both nevi and melanomas. 
The pathogenesis of sclerosis remains obscure but seems to be induced by melanocytes or an unusual host response 
in at least a subset of lesions. 
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Introduction
Fibrosis or sclerosis can be found in various types 
of melanocytic lesions, including persistent/recur-
rent nevi (partially excised or treated with other 
modalities)1-5, traumatized nevi6,7, desmoplastic 
nevi8,9, nevi arising against a background of lichen 
sclerosus or epidermolysis bullosa10-12, melanomas 
with regression and desmoplastic melanomas.13,14 
In addition, there is a subset of morphologically 
distinct and diagnostically challenging melano-
cytic lesions with focal or more diffuse sclerosis, 
which are characterized by an atypical intraepi-
dermal proliferation of melanocytes that often re-
sembles or is diagnostic for a melanoma in situ, fre-
quent effacement of the rete ridge pattern, atypical 
proliferation of nevoid melanocytes in the sclerotic 
area, and frequent remnants of a morphologically 
banal nevus adjacent to or beneath the sclerosis, 
creating a trizonal pattern (atypical intraepider-
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mal component, sclerotic dermal component and 
remnants of a banal looking melanocytic nevus 
below the sclerosis).15-17 Although the sclerosis may 
resemble regression or changes after previous trau-
ma, its pathogenesis remains obscure. Fabrizi et al. 
first reported a series of 19 such lesions, which they 
designated as “sclerosing nevi with pseudomela-
nomatous features”.15 The authors concluded that, 
despite their worrisome clinical and morphologic 
features, the lesions were probably benign nevi.
Although it has been suggested that a subset 
of sclerosing melanocytic lesions may represent 
melanomas (“sclerosing melanomas with nevoid 
features”), the full morphologic and biologic 
spectrum of sclerosing melanocytic lesions re-
mains unknown and sclerosing melanomas have 
not been well characterized.15-17 We present a se-
ries of 90 sclerosing melanocytic lesions collected 
prospectively, with a systematic morphologic, im-
munohistochemical analysis, fluorescent in situ 
hybridization (FISH) and follow-up. Our aim was 
to analyze the morphologic spectrum of scleros-
ing melanocytic lesions, especially the distinction 
between sclerosing melanocytic nevus and scle-
rosing melanoma, which has not been well docu-
mented.
Patients and methods
Case selection in histopathologic 
analysis
Ninety sclerosing melanocytic lesions, occurring in 
82 patients, were included in the study; 76 lesions 
were seen in routine practice and 14 lesions were 
outside consultation cases. Eighty-six lesions were 
collected from 2006 (when we first paid attention 
to this type of lesion) to 2014. After histopathologic 
revision of all other known excised melanocytic le-
sions in the 82 patients, four additional sclerosing 
melanocytic lesions were identified and included 
in the study. There was no history of previous treat-
ment or trauma in relation to any of the lesions.
The inclusion criterion was the presence of focal 
or diffuse dermal sclerosis within a melanocytic le-
sion, surrounding predominantly nests rather than 
single melanocytes of usually nevoid melanocytes. 
Lesions with large areas of fibrosis or sclerosis 
lacking melanocytes, or with greatly reduced num-
bers of melanocytes, were not included (excluding 
lesions with classical features of recurrent or pre-
viously traumatized nevi, or melanocytic lesions 
with regression).1,4-7 Sclerotic areas were not typical 
of regression in melanomas since there was dense 
sclerosis with mostly preserved melanocytes, al-
though there could be small adjacent areas sugges-
tive of regression.14
All lesions were histopathologically re-evalu-
ated by two of the authors (BGK and JP) in 2015. 
The following features were assessed histopatho-
logically: 1) atypical features of the intraepidermal 
portion of the lesion above the sclerosis (efface-
ment of the rete ridge pattern, cytological atypia 
of melanocytes, lentiginous proliferation, upward 
migration of melanocytes and presence of irregular 
intraepidermal nests of melanocytes), 2) extension 
of an atypical intraepidermal melanocytic prolifer-
ation outside the sclerosis, 3) maximum thickness 
of the sclerosis, 4) atypical features within the scle-
rosis (absence of maturation, presence of promi-
nent nucleoli, deep pigmentation, mitotic activity, 
distribution of melanocytic nests within the sclero-
sis), 5) presence of an unequivocal accompanying 
melanocytic nevus outside the sclerotic area, and 6) 
intraepithelial extension of melanocytes along the 
eccrine ducts. The number of mitoses in the scle-
rotic dermal component was reported per square 
millimeter according to the protocol for assess-
ment of mitotic activity in malignant melanomas.18 
Inflammatory infiltrate in the dermis was assessed 
as absent/mild or marked. Special attention was 
paid to possible more cellular foci in the sclerosis, 
a lamellar configuration of the sclerosis around the 
rete ridges and any features that would suggest 
regression (areas of more cellular sclerosis/fibrosis 
devoid of melanocytes, more pronounced inflam-
mation, proliferation of small vessels, fibrosis ar-
ranged parallel to the surface). 
Melanocytic lesions were on morphological 
grounds, together with HMB-45 expression and 
Ki67 proliferative activity when available (but 
without knowing the FISH results) categorized 
into one of three categories: nevus, melanoma, or 
melanoma with an accompanying nevus. The most 
important criteria in favor of a melanoma were: 1) 
extension of atypical intraepidermal melanocytic 
proliferation, diagnostic for an in situ melanoma 
beyond the sclerotic area, 2) prominent upward 
migration of intraepidermal melanocytes above 
the sclerosis, 3) severe cytological atypia of intraep-
idermal melanocytes above the sclerosis, 4) pres-
ence of mitoses within the sclerosis, 5) absence of 
maturation, 6) prominent nucleoli in the sclerosis, 
7) patchy or irregular diffuse HMB-45 positivity in 
the deepest part of the sclerotic component (i.e., ab-
sence of maturation) and 8) presence of Ki67 prolif-
erative activity in the melanocytes of the lower half 
of the sclerotic component.15,19
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Clinical data including data on sentinel lymph 
node biopsies and follow-up data were collected 
from patients’ medical records and national Cancer 
Registry. The study was performed on the archival 
tissue slides and blocks; therefore, no consent was 
required for this study. The study was approved by 
the Republic of Slovenia National Medical Ethics 
Committee (N23k/03/12 bis; date 03-13-2012).
Immunohistochemistry
A representative tissue block, when available, was 
selected for immunohistochemistry, including dou-
ble Ki67/melan A staining (Ki67: DAKO, Glostrup, 
Denmark, clone MIB-1, dilution 1:50; melan A: 
DAKO, Glostrup, Denmark, clone A103, dilution 
1:10) and HMB-45 (DAKO, Glostrup, Denmark, 
clone HMB-45, dilution 1:20). Deparaffinization, an-
tigen retrieval, and staining with antibodies were per-
formed in an automatic immunostainer (Benchmark 
XT, Ventana Medical Systems Inc., Tucson, USA) in 
combination with treating sections with secondary 
antibodies and color development with horseradish 
peroxidase (ultraVIEW DAB Detection Kit, Ventana 
Medical Systems Inc., Tucson, USA) for Ki67 and al-
kaline phosphatase (ultraVIEW Red Detection Kit, 
Ventana Medical Systems Inc., Tucson, USA) for 
HMB-45 and melan A.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed using a four-probe 
assay from Abbott Molecular, Inc. (Des Plaines, IL, 
USA) targeting Ras responsive element binding 
protein-1 on 6p25 (Vysis®LSI® RREB1-Spectrum 
Red), V-myb myeloblastosis viral oncogene ho-
molog on 6q23 (Vysis®LSI® MYB-Spectrum Gold), 
cyclin D1 on 11q13 (Vysis®LSI® CCND1-Spectrum 
Green) and centromeric enumeration probe control 
for chromosome 6 (Vysis®LSI® CEP6-Spectrum 
Aqua). The FISH analysis was performed on 5 µm 
thick sections prepared from formalin fixed and 
paraffin embedded tissue according to the manu-
facturer’s recommendations and using criteria as 
previously described.20,21 The analysis was done on 
melanocytes in the sclerotic dermal component in 
41 lesions with available tissue. A lesion was con-
sidered to have a positive FISH result if any of the 
following criteria were met: 1) gain in RREB1 rela-
tive to CEP6 in more than 55% of tumor cell nuclei, 
2) gain in RREB1 in more than 29% of tumor cell 
nuclei, 3) loss of MYB relative to CEP6 in more than 
40% of tumor cell nuclei or 4) gain in CCND1 in 
more than 38% of tumor cell nuclei.20,21 To deter-
mine the sensitivity and specificity of the test, we 
analyzed 19 morphologically obvious melanomas 
(non-sclerosing superficial spreading and nodular) 
and 18 nevi (common acquired and with congeni-
tal features). The assay was positive in 16 of 19 mel-
anomas and in 4 of 18 nevi, with 84% sensitivity 
and 78% specificity.20,21 
Statistical analysis
Statistical analysis was performed with IBM SPSS 
Statistics 20 (International Business Machines 
Corp., New York, NY). Differences among groups 
in relation to other clinicopathologic parameters 
were analyzed by the Kruskal-Wallis test and χ2 
test.
Results
Ninety sclerosing melanocytic lesions occurred in 
82 patients; 33 (40%) females and 49 (60%) males 
(four patients had 2 lesions each and two patients 
had 3 lesions each). The age of the patients ranged 
from 21 to 89 years (median, 48 years). The lesions 
were most frequently located on the back (46 le-
sions), followed by abdomen (18 lesions), chest 
excluding breast (12 lesions), breast (5 lesions), 
lower extremities (4 lesions), inguinal region (2 le-
sions), retroauricular region (2 lesions) and upper 
extremities (1 lesion). Clinical diagnoses, available 
for 74 lesions, included nevus (18 lesions), dysplas-
tic nevus (21 lesions), melanoma (29 lesions) and 
non-melanocytic lesion (6 lesions). Thirteen pa-
tients (16%), including three with multiple scleros-
ing melanocytic lesions, had at least one additional 
(two patients had 3 and two patients had 2) non-
sclerosing superficial spreading melanoma, diag-
nosed previously, simultaneously or subsequently.
Histopathologic interpretation was difficult in 
most of the lesions (Figures 1-4). Morphologically, 
twenty-six lesions (29%) were diagnosed on revi-
sion as nevi (8 ordinary, 10 dysplastic, 6 congenital, 
2 Spitz), 19 lesions (21%) as melanomas and 45 le-
sions (50%) as melanomas with an adjacent nevus 
(10 ordinary, 6 dysplastic, 29 congenital). On revi-
sion, 8 lesions originally diagnosed as melanomas 
(with or without an adjacent nevus) were reclassi-
fied as nevi and 1 lesion originally diagnosed as a 
nevus was reclassified as a melanoma. 
Of the 64 melanomas (with or without an ac-
companying nevus), one was an in situ melanoma, 
3 Clark level 2, 29 Clark level 3 and 31 Clark level 
4. The Breslow thickness of the 63 invasive melano-
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Sclerosis in the dermis was diffuse (involv-
ing the entire dermal part of the lesion) in 39 le-
sions (43%), including 15 of 26 nevi (58%), 17 of 
19 melanomas (89%) and 7 of 45 melanomas with 
an accompanying nevus (16%), and focal in other 
lesions. It never extended beyond a melanocytic 
lesion. The thickness of sclerosis ranged from 0.3 
to 1.8 mm (median, 0.7 mm) and did not differ 
among the three diagnostic groups. A trizonal pat-
tern (atypical intraepidermal component, sclerotic 
dermal component and remnants of a banal nevus 
below the sclerosis) was noted in 43 lesions (48%) 
(Figures 1, 3 and 4). Sclerotic areas were generally 
hypocellular, except for 3 melanomas in which the 
sclerosis was focally more cellular and edematous, 
indicating an early stage of sclerosis. A lamellar 
configuration of sclerosis around rete ridges was 
noted in 8 lesions (9%) (Figure 2). Very focal areas 
suggestive of regression were noted in 26 lesions 
(32%), predominantly melanomas. 
There was partial or complete effacement of the 
rete ridge pattern in 38 (42%) and 43 (44%) of the 
cases, respectively. Except for 2 Spitz nevi and 3 
melanomas, melanocytes within the sclerosis were 
relatively small, nevoid, with various degrees of 
hyperchromasia and variously prominent nucleoli 
(Table 1, Figures 3C, 3D, 4C). Compared to the sur-
rounding nevus outside the sclerosis (when pre-
sent), melanocytes within the sclerosis were usu-
ally slightly larger, with more conspicuous pale cy-
toplasm (Figure 4C). Dermal mitotic figures within 
the sclerosis were found in 17 of 64 melanomas (1 
per square millimeter in 11 lesions, 2 in 2 lesions 
and 3 in 1 lesion) and in 1 of the 26 nevi (1 per 
square millimeter) (Table 1). Nests in the sclerosis 
varied in size, but very large expansive nodules 
were absent. In some lesions, nests were oriented 
parallel to the surface of the skin. Extension of 
melanocytes along the eccrine ducts (not used as a 
diagnostic criterion) was found significantly more 
frequently in melanomas (Figure 3B, Table 1). 
All lesions were treated by surgical excision. A 
re-excision was performed in 65 of 85 (76%) lesions 
with available information. A sentinel lymph node 
biopsy was performed for 17 lesions (16 melano-
mas, including all 13 melanomas with Breslow 
thickness ≥1 mm, and 1 nevus that was initially in-
terpreted as a melanoma) and was negative in all 
cases. The Breslow thickness of melanomas with 
sentinel lymph node biopsies ranged from 0.6 to 
1.8 mm (median, 1.2 mm) and was ≥ 1 mm in 13 
cases and > 1.5 mm in only one case. 
Follow-up data for disease free survival were 
available for 66 lesions, with a follow-up period 
FIGURE 2. Sclerosing melanocytic nevus from the abdomen of a 53-year-old man, 
with negative the FISH assay. (A), (B) There is lamellar-type sclerosis involving the 
entire dermal component. 
A B
mas ranged from 0.4 to 1.8 mm (median, 0.75 mm). 
It corresponded to the thickness of sclerosis in all 
except one case, in which the Breslow thickness 
exceeded the thickness of the sclerosis. Of the 45 
melanomas with an accompanying nevus outside 
the sclerosis, the nevus was located below the scle-
rosis in 22 cases, adjacent to it in 11 cases or both 
in 12 cases. No ulceration was present in any of the 
lesions. 
Key clinical, morphologic and immunohisto-
chemical features, and the FISH results in relation 
to the three diagnostic categories are shown in 
Table 1. Among 14 lesions diagnosed on morpho-
logical grounds as melanomas and positive FISH 
results, one FISH criterion was met in 6, two crite-
ria in 6 and three criteria in 2 cases. Gain in RREB1 
in more than 29% of tumor cell nuclei was found in 
9 lesions, gain in RREB1 relative to CEP6 in more 
than 55% of tumor cell nuclei in 6 lesions, loss of 
MYB relative to CEP3 in more than 40% of tumor 
cell nuclei in 7 lesions, and gain in CCND1 in more 
than 38% of tumor cell nuclei in 2 lesions. Clinical 
and histopathologic parameters in relation to FISH 
results in 41 lesions with FISH analysis of the scle-
rotic component are shown in Table 2.
A B
FIGURE 1. Sclerosing melanocytic nevus from the abdomen of a 22-year-old 
woman, with negative FISH assay. (A) There is a trizonal pattern, maturation and an 
atypical intraepidermal component above the sclerosis, which does not extend 
beyond the sclerosis. (B) HMB-45 stain shows maturation in the dermal component.
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from 1 to 106 months (median, 19 months), and for 
overall disease specific survival for 75 lesions, with 
a follow-up period from 12 to 131 moths (median, 
77 months). During the follow up period, there 
was no evidence of disease progression in any of 
the patients that could undoubtedly be attributed 
to the lesions studied. 
Discussion
We present 90 melanocytic lesions, which we des-
ignated morphologically as sclerosing melanocytic 
nevi or sclerosing melanomas. The lesions are 
characterized by an area of sclerosis in the der-
mis, with nests of atypical, in most cases nevoid 
TABLE 1. Clinical and histopathologic parameters in relation to morphological diagnostic categories
Parameter, n (%) All Nevus Melanoma Melanoma with nevus P -value
N (%) 90 26 (29) 19 (21) 45 (50)
Age of the patients (years) (median; range) 48; 21-89 38; 22-53 60; 21-89 51; 26-85 < 0.001
Maximum diameter* (mm) (median; range) 9; 2-29 7; 2-14 8; 3-29 11; 4-25 0.014
Location 0.076
Back 46 (51) 9 (35) 9 (47) 28 (62)
Other 44 (49) 17 (65) 10 (53) 17 (38)
Extension along eccrine ducts** 49/77 (64) 5/21 (24) 14/17 (82) 30/39 (77) < 0.001
Evidence of regression 29 (32) 1 (4) 12 (63) 16 (36) /
Lamellar sclerosis 8 (9) 6 (23) 0 2 (4) /
Marked inflammation in the sclerosis 27 (30) 2 (8) 6 (32) 19 (42) /
Maturation in the sclerosis 50 (56) 25 (96) 8 (42) 17 (38) /
Dermal mitoses present 18 (20) 1 (4) 4 (21) 13 (29) /
Prominent nucleoli in the sclerosis 52 (58) 5 (19) 16 (84) 31 (69) /
Intraepidermal component adjacent to the sclerosis /
Not atypical 18 (20) 17 (65) 1 (5) 0
Atypical 17 (19) 9 (35) 1 (5) 7 (16)
Melanoma in situ 55 (61) 0 17 (89) 38 (84)
Severe cytological atypia in the epidermis above the sclerosis 68 (76) 9 (35) 19 (100) 40 (89) /
Lentiginous growth above the sclerosis 82 (91) 19 (73) 19 (100) 44 (98) /
Upward migration in the epidermis above the sclerosis /
No 12 (13) 9 (35) 1 (5) 2 (4)
Lower half 11 (12) 7 (27) 1 (5) 3 (7)
Focally in the upper half 23 (26) 9 (35) 5 (26) 9 (20)
Prominent full thickness 44 (48) 1 (4) 12 (63) 31 (69)
HMB-45 in the sclerotic component 60 19 11 30 /
Patchy, irregular 37 (62) 6 (32) 10 (91) 21 (70)
Maturation or completely absent 23 (38) 13 (68) 1 (9) 9 (30)
Ki67 in the sclerotic component 66 19 13 34
No positivity in the lower half 51 (77) 19 (100) 8 (62) 24 (71) /
Some positive melanocytes in the lower half, <5% overall 13 (20) 0 4 (31) 9 (26)
>5%, no gradient with the depth 2 (3) 0 1 (7) 1 (3)
Four-probe FISH in the sclerotic component 41 16 7 18 0.001
Positive 14 (34) 0 3 (43) 11 (61)
Negative 27 (66) 16 (100) 4 (57) 7 (39)
* available for 81 lesions; **no eccrine ducts were identified within or adjacent to sclerotic dermal component in 13 lesions
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melanocytes, an atypical intraepidermal compo-
nent and, in more than half of the cases, a banal 
looking nevus beneath or adjacent to the sclerosis. 
Sclerosing melanocytic lesions are most striking 
when banal looking nevus remnants are present 
beneath the sclerosis (in 48% of our lesions), creat-
ing a trizonal pattern. Fabrizi et al. reported 19 sim-
ilar lesions, which they called sclerosing nevi with 
pseudomelanomatous features.15 However, the 
authors included in their study only lesions with 
the presence of a nevus below or adjacent to the 
sclerosis, an absence of cytological atypia or promi-
nent nucleoli in sclerotic areas and an absence of 
significant mitotic activity. Forty-two lesions, se-
lected on the basis of features of dysplastic nevus 
and pronounced fibrosis, were reported by Ko et al. 
and termed dysplastic nevi with florid fibroplasia 
and pseudomelanomatous features.16 We collected 
our cases prospectively and included all lesions 
with an area of sclerosis in the dermis (similar to 
the sclerosis described in the above mentioned 
studies), which was different from what one clas-
sically observes in regressing melanomas or recur-
rent/previously traumatized nevi.1-4,7,14 Our series 
therefore broadens the spectrum of sclerosing mel-
anocytic lesions, including lesions with sclerosis of 
the entire dermal component (without an adjacent 
remnant of banal nevus), and more prominent cy-
tological and architectural atypia.15-17
Histopathologic interpretation of most scleros-
ing lesions is challenging because of overlapping 
features between an atypical nevus and a mela-
noma.15,17,22,23 Morphologic interpretation may de-
pend on the point of view of whether the sclerosis 
represents regression, previous chronic trauma, 
exaggerated lamellar fibrosis seen in dysplastic 
nevi, or other unknown factors.15-17,24 Most difficult 
and clinically important is interpretation of the 
melanocytic component in the sclerotic area. Many 
sclerosing melanocytic lesions display morpho-
logic features that are in the routine practice used 
to differentiate melanomas from nevi, including 
presence of a melanoma in situ adjacent to the scle-
rosis (61% of our lesions), prominent full-thickness 
pagetoid spread above the sclerosis (48% of our le-
sions), absence of maturation (44% of our lesions), 
presence of prominent nucleoli (58% of our lesions) 
and mitotic activity in the sclerotic area (20% of our 
lesions). Patchy or irregular diffuse positivity for 
HMB-45 in the dermal component and an absence 
of a gradient in Ki67 labeling have been considered 
useful clues for melanoma.19 However, there is 
overlap in the staining patterns between nevi and 
melanomas and their discriminatory value may 
be lower in thin, ambiguous and diagnostically 
difficult lesions.25 An aberrant, irregular diffuse 
expression of HMB-45 was found in melanocytic 
nevi after liquid nitrogen cryotherapy.19 Although 
it is frequently stated that the Ki67 index is typi-
cally more than 5% in invasive melanomas, Ki67 
labelling may be less than 5% or even completely 
absent in the invasive component in a significant 
proportion of thin melanomas (Breslow thickness 
of less than 1 mm).25 In most of our lesions, it was 
less than 5%, usually with only a few positive mel-
anocytes.
Although an atypical proliferation of intraepi-
dermal melanocytes above the sclerosis can, simi-
larly to recurrent/persistent or previously trau-
matized nevi, be attributed to the sclerosis itself, 
cytological atypia and, in particular, prominent 
pagetoid growth in our sclerosing melanocytic le-
A B
C D
FIGURE 3. Sclerosing melanoma from the abdomen of a 67-year-old man. (A) There 
are remnants of a nevus below the melanoma (arrow) and a trizonal pattern. (B) 
Some melanocytes are in the epithelium of an eccrine duct (arrow). (C) Melanocytes 
within sclerosis are atypical, with prominent nucleoli. (D) There is a mitotic figure 
(arrow). (E) HMB-45 staining is irregular diffuse in the sclerotic dermal component 
(melanoma) but negative in the nevus below (arrow). There is prominent pagetoid 
spread in the epidermis. (F) The FISH assay was positive, showing loss of MYB (gold) 
relative to CEP6 (aqua) in 57% of tumor cell nuclei.
E F
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sions frequently exceeded atypical features seen in 
recurrent or previously traumatized nevi.1,3,4,6,17 In a 
large series of recurrent melanocytic nevi, pagetoid 
growth was observed in 6% of the lesions, in con-
trast to 87% of our sclerosing lesions.4 In two pre-
vious studies of sclerosing melanocytic nevi, some 
degree of pagetoid spread was identified in 24% 
and 47% of cases, respectively.15,16 In previous stud-
ies, the morphologic features of the intraepider-
mal melanocytic component outside the sclerosis 
were not specifically reported; in our series, it was 
atypical in 80% of cases, and in 61% to the degree 
of a melanoma in situ. Although atypia above the 
sclerosis could be attributed to some degree to the 
sclerotic process in the dermis and may therefore 
be less relevant for morphologic interpretation, an 
atypical intraepidermal component that extends 
outside the area of sclerosis is strongly suggestive 
of a melanoma in situ.4,19 We also noted significant-
ly more frequent extension of melanocytes along 
the eccrine ducts in lesions that we diagnosed as 
melanomas.1
The four-probe FISH assay was positive in 14 of 
25 (56%) of the lesions diagnosed morphologically 
as melanomas and in none of 16 nevi, providing 
additional evidence that sclerosing melanocytic le-
sions include both nevi and melanomas. Although 
the four-probe FISH assay has been reported to 
have a sensitivity of about 85% for diagnosing un-
equivocal melanomas, its sensitivity is much lower 
(about 50%) in ambiguous melanocytic lesions and 
in some melanoma types, including desmoplas-
tic melanoma.20,21,26 Negative FISH results do not 
therefore rule out a melanoma. Nevertheless, al-
though the sensitivity of the FISH assay for scleros-
ing melanomas may be lower than for unequivocal 
ordinary melanomas, it is likely that some of our 
lesions had been morphologically overdiagnosed 
as melanomas. Although the FISH assay has been 
reported to be relatively specific in differentiating 
melanomas from nevi (with reported specificity 
around 95%, and 78% specificity in our test series 
of 18 nevi), a positive FISH assay per se is not diag-
nostic for a melanoma and should be interpreted in 
correlation with morphologic features.20,21,26
The thickness of sclerosis ranged from 0.3-1.8 
mm (median 0.7 mm).15-17 Sclerosis was either focal 
(57%) or diffuse (43%), involving the entire dermal 
part of the melanocytic lesion. The etiology of scle-
rosis remains elusive. There is usually no history 
of previous trauma or treatment, and the pattern 
of sclerosis usually differs from scars after previ-
ous mechanical trauma, surgery or other treatment 
modalities such as cryotherapy.1,4,5-7,15-17 In recur-
rent nevi, fibrosis tends to be more cellular, with 
larger areas devoid of melanocytes.4 Although 
sclerosis can be related to previous unnoticed or 
chronic trauma, it is our impression that the scle-
rosis cannot be explained by previous trauma in 
most of our lesions.15 In contrast to our lesions, 
cytological atypia and pagetoid spread tend to 
be only rarely and focally present in traumatized 
nevi.6 Sclerosis sometimes displays a lamellar con-
figuration (in 9% of our lesions), suggesting an ex-
aggerated lamellar fibrosis, as seen in dysplastic 
nevi.16,27 Sclerosis in sclerosing melanocytic lesions 
differs from fibrosis typically seen in regressing 
melanomas. It usually has a very dense, sclerotic 
quality, lacks vascular proliferation and, most of 
all, melanocytes in the sclerotic areas tend to be 
preserved.4,13-15 Nevertheless, small areas sugges-
FIGURE 4. Sclerosing melanoma from the back of a 70-year-old female. (A) There 
are remnants of a nevus below sclerosis (arrow). (B) Melanocytes in the sclerosis 
do not show maturation and (C) are larger with irregular nuclei and prominent 
nucleoli compared to melanocytes in the adjacent nevus (left). (D) HMB-45 stain 
shows pagetoid spread in the epidermis, but is completely negative in the dermis. 
(E) Ki67 (brown)/melan A (red) shows no proliferative activity in the melanocytes in 
the deepest aspect of the sclerotic component; note less intense melan A positivity 
in the nevus below the melanoma (arrow). (F) The FISH assay was positive, showing 
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tive of regression have been found adjacent to scle-
rotic areas in one third of cases.17 In some lesions, 
the contours of the sclerosis follow perfectly the 
contours of the melanocytic lesion, and sclerosis 
typically does not extend beyond the confines of 
sclerosing melanocytic lesions. This argues against 
a post-traumatic sclerosis and suggests that there 
may be some melanocyte-related factors inducing 
sclerosis. 
The lesions described in the present study share 
some features with desmoplastic nevi (also called 
sclerotic and sometimes sclerosing); however, there 
are several distinctive features.8,9,24 Desmoplastic 
nevi tend to be predominantly dermal, the junc-
tional component is not atypical, sclerosis involves 
the entire dermal component and is symmetrically 
distributed. Single melanocytes predominate, par-
ticularly in the deepest aspects of the lesion. 
The age distribution of sclerosing melanocytic 
lesions is wide, from 18-91 years, with a male to 
female ratio of approximately 1.5-2:1.15-17 From 37% 
to 72% of the lesions are located on the back, al-
though they can be located at many other sites.15-17 
The lesions are relatively large; their largest diame-
ter ranges from 2-29 mm, with a median of approx-
imately 10 mm.15 In our series, lesions diagnosed 
morphologically as melanomas were significantly 
larger than nevi and occurred in significantly older 
patients than nevi. Clinically, the lesions are often 
suspicious for a melanoma because of an uneven 
pigmentation and whitish areas suggestive of re-
gression.15,16,19,24 Remnants of nevus tissue beneath 
or adjacent to the sclerosis are of congenital, com-
mon acquired, dysplastic, and rarely Spitz type.15-17
We could not prove progression of the disease 
attributable to the sclerosing melanomas in any of 
our patients. However, the median follow-up for 
recurrence-free survival was relatively short and 
the number of cases with sentinel lymph node 
biopsy small. Additionally, on the basis of classic 
prognostic parameters in melanoma, sclerosing 
melanomas tend to be low-risk lesions, since the 
Breslow thickness is < 1 mm in most lesions, ulcera-
tion is not present and mitotic activity is identified 
in only a minority of cases.18 The absence of dis-
ease progression does not therefore in itself argue 
against sclerosing melanomas.15,17 
Conclusions
In conclusion, we present a large series of rare 
but peculiar, diagnostically challenging and not 
widely recognized sclerosing melanocytic lesions. 
The pathogenesis of sclerosis remains obscure. It 
may be in some lesions (nevi) related to chronic 
unnoticed trauma, but it seems to be induced by 
melanocytes or an unusual host response in at 
TABLE 2. Clinical and histopathologic parameters in relation to FISH results in 41 lesions with FISH analysis of the sclerotic component
Parameter, n (%) All FISH-positive FISH-negative P -value
N (%) 41 14 27
Age of the patients (years) (median; range) 48; 22-89 51; 42-89 48; 22-77 0.196
Thickness of sclerosis (mm) (mean; range) 0.85; 0.5-1.5 1.0; 0.7-1.5 0.8; 0.5-1.3 0.002
Location 0.096
Back 25 (61) 11 (79) 14 (52)
Other 16 (39) 3 (21) 13 (48)
Extension along eccrine ducts 21/38 (55) 11/14 (71) 10/24 (42) 0.026
Evidence of regression 8 (20) 4 (29) 4 (15) 0.411
Maturation in the sclerosis 29 (71) 7 (50) 22 (81) 0.068
Dermal mitoses present 10 (24) 5 (36) 5 (19) 0.267
Prominent nucleoli in the sclerosis 20 (49) 11 (79) 9 (33) 0.009
Melanoma in situ adjacent to the sclerosis 23 (56) 13 (93) 10 (39) 0.001
Severe cytological atypia in the epidermis above the sclerosis 27 (66) 12 (86) 15 (56) 0.053
Prominent full thickness upward migration in the epidermis above the sclerosis 19 (22) 10 (71) 9 (33) 0.026
Patchy irregular HMB-45 in the sclerotic component 22/38 (58) 11/13 (85) 11/25 (44) 0.016
No Ki67 positivity in the lower half of the sclerotic component 28/39 (72) 7/14 (50) 21/25 (84) 0.033
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least a subset of lesions. Many sclerosing melano-
cytic lesions display morphologic features that are 
suggestive or diagnostic for a melanoma, includ-
ing the presence of a melanoma in situ extending 
beyond the sclerotic area, prominent full-thickness 
pagetoid spread above the sclerosis and an absence 
of maturation in the sclerotic area, with atypical 
melanocytes, prominent nucleoli an sometimes 
mitoses. Approximately half of the more atypical 
lesions also show a positive four-probe FISH assay, 
providing additional evidence in favor of scleros-
ing melanomas. Although we could not prove pro-
gression of the disease attributable to the lesions 
diagnosed as sclerosing melanomas, our study 
provides strong evidence, based on morphological 
criteria and a positive four-probe FISH assay, that 
sclerosing melanocytic lesions include both nevi 
and melanomas. A four-probe FISH assay may as-
sist in diagnosing these lesions when they cannot 
be confidently diagnosed as either nevus or mela-
noma by morphologic features. An awareness of 
the morphologic features of sclerosing melanocytic 
lesions and their overlap between nevus and mela-
noma is important for a more cautious histopatho-
logic interpretation. It may be more appropriate 
to use the terms “atypical sclerosing melanocytic 
lesion” or “sclerosing melanocytic lesion with un-
known malignant potential” when a sclerosing 
melanocytic lesion cannot be confidently classified 
as either a nevus or a melanoma. 
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